Building a Billion-Dollar Biologics Business

PE Perspectives/White Papers
Case Studies

Building a Billion-Dollar Biologics Business

How NewSpring Healthcare capitalizes on the industry’s need for modernized solutions that lower costs and improve patient outcomes

It’s no secret that the healthcare industry is complex, inefficient, and ripe for disruption. NewSpring Healthcare empowers the growth of lower-middle market businesses bringing innovative, cost-saving, and life-changing solutions that will advance healthcare forever.

Building a Billion-Dollar Biologics Business

When we invested in Paragon Bioservices, the company had a small manufacturing facility and a few scientists and engineers on staff. In just five years, NewSpring helped grow the company into a $1.2bn business with a 200K square-foot GMP (Good Manufacturing Practices) manufacturing facility capable of commercial-scale gene therapy production.

Why we invested

Paragon’s expertise addressed a significant need in an attractive and growing market given the rising demand for biologics.

Paragon had a strong brand and client base built largely through word-of-mouth with significant opportunities for future growth and client expansion.

Paragon’s specialized facility had strong technical capabilities and the ability to deliver services in segments that weren’t being served by other U.S. firms.

Finding efficient scale

The key to growing Paragon was finding efficient scale and professionalizing the company while taking calculated risks. Here’s how we did it:

1. HIRED A TEAM BUILDER
Pre-deal, we negotiated to bring on Pete Buzy as COO and quickly promoted him to CEO to run operations, build out the second-tier management team, and scale the business.

2. TRANSFORMED THE BUSINESS MODEL
We shifted Paragon's focus to emerging gene therapy companies and their unmet need for contract manufacturers given insufficient manufacturing capacity in the market.

3. INVESTED IN GENE DELIVERY DRUGS/THERAPEUTICS
We took the calculated risk to be first movers in gene therapy, for which we felt the FDA was ready to give approvals.

4. CREATED EFFICIENCIES AND EXPANDED MANUFACTURING SPACE
We invested in technology and additional facilities to grow from an academic lab-like setting to a professionalized business.

A billion-dollar exit

AT INVESTMENT:
  • <$20mm Revenue and EBITDA negative
  • World-class scientists and strong concept
  • 53K-square foot manufacturing facility, primarily producing early phase clinical trial material
  • Revenues coming from broad sources and predominantly in-bound calls
AT EXIT:
  • $200mm+ Revenue and 25%+ EBITDA margins
  • World-class commercialized business
  • 200K+ square foot GMP manufacturing facility capable of commercial-scale gene therapy production
  • Strong sales team and partnerships with over 20 of the world's top pharmaceutical and biotechnology companies

About NewSpring Healthcare

NewSpring Healthcare invests in innovative companies in the lower-middle market that improve the delivery of healthcare or bend the cost curve through technology and human capital efficiencies.

SAMPLE PORTFOLIO COMPANIES IN OUTSOURCED SERVICE PROVIDER VERTICAL:


ADAM VEVERKA
Partner, Business Development
aveverka@newspringcapital.com
(610) 567-2392

ADAM VEVERKA

Partner, Business Development

aveverka@newspringcapital.com

(610) 567-2392


MIKE O'NEILL
Managing Director, Fundraising
moneill@newspringcapital.com
(610) 947-6227

MIKE O'NEILL

Managing Director, Fundraising

moneill@newspringcapital.com

(610) 947-6227


Related Articles

Celebrating 25 Years: 25 Tips for Growing Lower-Middle-Market Businesses

For 25 years, NewSpring has remained steadfast in our commitment to the lower-middle market, where...

Operating Advice

May 03, 2024

Read more

Revolutionizing Records Release Solutions

It’s no secret that the healthcare industry is complex, inefficient, and ripe for disruption....

PE Perspectives/White Papers
Case Studies

January 10, 2024

Read more

Get the latest
NewSpring news

arrow_forwardSubscribe

Get the latest news delivered to your inbox

arrow_forward Subscribe now